Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04899687 · ClinicalTrials.gov registry record · Phase 2
Study of Dextromethorphan in OCD and Related Disorders
A Phase 2 study of Obsessive - Compulsive Disorder and Illness Anxiety Disorder, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT04899687 is a Phase 2 study of Obsessive - Compulsive Disorder and Illness Anxiety Disorder that is actively recruiting participants, run by Stanford University. The registered enrollment target is 60 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04899687, a Phase 2 study of Obsessive - Compulsive Disorder and Illness Anxiety Disorder, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.
Conditions Studied
Interventions
- DRUG Fluoxetine
- DRUG Dextromethorphan
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-01-20 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04899687
The ClinicalTrials.gov registry entry for NCT04899687 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (97% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Fluoxetine is the first listed.
NCT04899687 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04899687 about?
NCT04899687 is a clinical study titled "Study of Dextromethorphan in OCD and Related Disorders". The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.
What is the current status of trial NCT04899687?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-01-20. Estimated completion is 2026-12-01.
What conditions does trial NCT04899687 study?
This clinical trial studies the following conditions: Obsessive - Compulsive Disorder, Illness Anxiety Disorder, Body Dysmorphic Disorders, Somatic Symptom Disorder.
What interventions are being tested in trial NCT04899687?
The interventions under investigation include: Fluoxetine (DRUG), Dextromethorphan (DRUG).
Who is sponsoring clinical trial NCT04899687?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04899687 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive - Compulsive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)
RECRUITING · Phase 2
-
Efficacy of Nitrous Oxide in OCD: Pilot Study
RECRUITING · Phase 2
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)
RECRUITING · Phase 2
-
A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Understanding How Ketamine Brings About Rapid Improvement in OCD
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.